Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Menendez-Gonzalez, Manuela; *; 1 | Castro-Santos, Patriciab; 1 | Suarez, Anac | Calatayud, María Teresad | Perez-Pinera, Pabloc | Martinez, Martaa | Ribacoba, Reneea | Gutierrez, Carmenb; c
Affiliations: [a] Department of Internal Medicine, Hospital Álvarez-Buylla, Mieres, Spain | [b] Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain | [c] Department of Functional Biology, Universidad de Oviedo, Oviedo, Spain | [d] Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain
Correspondence: [*] Corresponding author: Manuel Menendez Gonzalez, Hospital Alvarez-Buylla, Servicio de Medicina Interna, Unidad de Neurología, Murias s/n, Mieres, 33616, Spain. E-mail: [email protected].
Note: [1] Manuel Menendez-Gonzalez and Patricia Castro-Santos contributed equally to this paper.
Abstract: The search for molecular biomarkers for diagnosing and classifying dementias is becoming a high priority need. Neurosin (Kallikrein 6, hk6) is one molecule with promising preliminary results since its levels in brain tissue, cerebrospinal fluid and blood have been found to be abnormal in Alzheimer's disease (AD). In this study, we measured plasmatic levels of neurosin in healthy individuals and patients with cognitive symptoms independently of what the final diagnosis was. We collected plasma samples from 228 controls and 447 patients finally diagnosed with either AD, Mild Cognitive Impairment, Dementia with Lewy Bodies or Parkinson-Dementia, Frontotemporal Dementia, Huntington's disease, Primary Progressive Aphasia, Corticobasal degeneration, Creutzfeldt-Jakob's disease or Pseudodementia. We found that plasmatic levels of neurosin increase with age in healthy individuals and decrease in patients with AD. Plasmatic levels of neurosin differ significantly between AD and Vascular Dementia, Pseudodementia and the control group. Analyses comparing any other form of neurodegenerative dementia to the AD group did not show significant differences. In conclusion, measurement of plasmatic levels of neurosin is useful to distinguish AD patients from subjects without neurodegenerative dementia (either Pseudodementia, Vascular Dementia or controls) although it is not useful to distinguish among neurodegenerative dementias.
Keywords: Alzheimer's disease, biomarker, dementia, mild cognitive impairment, neurosin
DOI: 10.3233/JAD-2008-14106
Journal: Journal of Alzheimer's Disease, vol. 14, no. 1, pp. 59-67, 2008
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]